Company attributes
Other attributes
Mission Therapeutics is a drug development and discovery company that engages in selectively targeting deubiquitylating enzymes with small molecule inhibitors to treat patients with serious and life-threatening diseases.
Mission Therapeutics has a strategy of creating value by advancing its pipeline programs via early clinical development, and preferentially with a patient selection strategy to improve the probability of demonstrating early signs of efficacy.
Mission Therapeutics has established itself as a leader in the deubiquitylating enzymes field. The company has a group of scientists who have the expertise in translating new scientific concepts around the physiological and pathophysiological roles of DUBs from the research laboratory to the clinic. Mission has developed a proprietary multi-dimensional platform to generate DUB inhibitors. The company is currently focused on developing DUB inhibitors for treating multiple disease indications that incude kidney disease, rare mitochondrial diseases neurodegenerative disease, and fibrosis.
